Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Meanwhile, inactivation of these genes using Ad-K5cre in basal cells leads to the development of SCLC, thus differentially influencing the lung cancer type developed. 31611390 2019
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE The expressions of SDPR-AS and SDPR in different subtypes of lung cancer (AC, SCC, LCC and SCLC) tissues and cells were determined. 31352804 2019
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Individual level data analysis was performed on 25,430 patients with NSCLC and 2787 patients with SCLC from 16 studies of the International Lung Cancer Consortium evaluating the association between various BMI variables and lung cancer overall survival, reported as adjusted hazard ratios (aHRs) from Cox proportional hazards models and adjusted penalized smoothing spline plots. 31163278 2019
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE EGFR/TP53/RB1-mutant lung cancers are at unique risk of histologic transformation, with 25% presenting with de novo SCLC or eventual small cell transformation. 31228622 2019
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC. 29729229 2018
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE A total of 45 patients with lung cancer were recruited and stratified in to a non-small cell lung cancer (NSCLC) and an SCLC group. 29399130 2018
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE SCLC accounts for 15% and 20% of all lung cancers, with combined SCLC (CSCLC) comprising 2% to 5%. 29101056 2018
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE SCLC accounts for almost 15% of lung cancer cases in the United States. 29902534 2018
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE Significant excess distant relatedness was observed for all lung cancer histologic subgroups analyzed except for the SCLC subset (p = 0.213). 29626620 2018
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE Response rate was 39% (43/111).Among respondents, 60% have at least 6 years of work experience following residency; 77% and 71% respectively see > 50 lung cancer and > 11 SCLC cases annually. 28087132 2017
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE The current WHO classification of lung cancer states that a diagnosis of SCLC can be reliably made on routine histological and cytological grounds but immunohistochemistry (IHC) may be required, particularly (1) in cases in which histologic features are equivocal and (2) in cases in which the pathologist wants to increase confidence in diagnosis. 27998793 2017
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE SCLC accounts for 15% of lung cancer worldwide. 29173760 2017
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE In the stratified analysis by ethnicity, gender, histological types of lung cancer and smoking status, a significant association was found in Asians and smokers, not in Caucasian or mixed population, Male, Female population, lung AC, SCC, SCLC or non-smokers. 24566690 2014
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE The classifier, termed SCLC-specific hub network (SSHN), robustly separates SCLC from other lung cancer types across multiple datasets and multiple platforms, including RNA-seq and shotgun proteomics. 24564859 2013
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Peripheral blood samples from 21 neuroendocrine lung cancer affected patients (14 SCLC, 6 LC and 1 LCNEC) subjected to scintigraphy with (111)In-DTPA-D-Phe(1)-octreotide (OctreoScan) and 24 healthy blood donors were investigated by RT-qPCR. mRNA levels for SSTR2a, SSTR3 and SSTR5 were measured in peripheral blood samples with a relative quantification method using plasmid dilutions as calibration curves and GAPDH as reference gene. 21503779 2011
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 AlteredExpression disease BEFREE In all lung cancer specimens, alpha 3 integrin was strongly expressed in ADC, SCC and BAC, but was infrequent in SCLC. alpha 4 integrin was solely expressed in BAC. alpha 5 and beta1 integrins were expressed in all four histological types of lung cancer specimens. 19674850 2009
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 AlteredExpression disease BEFREE High levels of nuclear immunohistochemical expression of NF-kappaB p65 were detected in the lung cancers, with significantly higher levels in SCLCs compared with NSCLCs (P<.0001). 17078054 2006
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Nine human lung cancer cell lines were examined (four SCLC and five NSCLC cell lines). cDNA-based sequencing of the entire p53 gene was performed. 12820372 2003
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Among histologic types of lung cancer, a weak protective effect was found for both adenocarcinoma (OR = 0.81, CI 0.55-1.19) and SCC (OR = 0.82, CI 0.56-1.21); a stronger and significant effect was found for SCLC (OR = 0.58, CI 0.36-0.95; p = 0.029). 12432558 2002
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40). 12467239 2001
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas. 9873831 1998
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations. 9794233 1998
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE We studied the cytogenetic and genetic alterations in cell lines derived from three unusual subtypes of lung cancer: including carcinoids, non-small cell lung cancers expressing NE properties (NSCLC-NE) and extrapulmonary small cell cancers (ExPuSC) and compared them with those of SCLC and NSCLC lines. 7762988 1995
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 GeneticVariation disease BEFREE More recent data using DNA probes specific for the cytogenetic deletion on chromosome 3, previously identified in only SCLC, suggests that this deletion 3p 14-23 is common to most, if not all, cell types of lung cancer. 3289122 1988
Entrez Id: 7864
Gene Symbol: SCLC1
SCLC1
0.100 Biomarker disease BEFREE Two major conclusions have emerged from these studies: (1) considerable heterogeneity exists within a given tumor type (eg, SCLC) in the expression of a given biomarker, and (2) overlap in the expression of biomarkers exists between cells of SCLC and non-SCLC, suggesting a common stem cell for all types lung cancer. 3007041 1986